PMID- 17706207 OWN - NLM STAT- MEDLINE DCOM- 20080715 LR - 20231213 IS - 1556-5653 (Electronic) IS - 0015-0282 (Linking) VI - 89 IP - 5 Suppl DP - 2008 May TI - Increased frequency of human leukocyte antigen-E inhibitory receptor CD94/NKG2A-expressing peritoneal natural killer cells in patients with endometriosis. PG - 1490-6 AB - OBJECTIVE: To analyze the frequency of peritoneal natural killer (NK) cells expressing the human leukocyte antigen (HLA)-E receptor CD94/NKG2A in patients with endometriosis. DESIGN: Case-control study. SETTING: University hospital. PATIENT(S): Stage III and stage IV endometriosis, according to the revised American Society for Reproductive Medicine classification, was laparoscopically and histologically confirmed in 11 and 9 patients, respectively; 13 subjects without endometriosis were selected for the control group. INTERVENTION(S): Collection of peripheral venous blood, peritoneal fluid, endometriotic tissue, and normal endometrium in subjects undergoing laparoscopy. MAIN OUTCOME MEASURE(S): Surface expression levels of CD94/NKG2A and CD94/NKG2C were detected by three-color cytofluorometric analysis. Semiquantitative HLA-E messenger RNA expression analysis was performed in endometriotic lesions and in eutopic endometrium. NK cell-mediated cytotoxic activity toward HLA-E positive target, DT360 cell line, was also determined. RESULT(S): In women with endometriosis, the percentage of CD94/NKG2A-positive peritoneal NK cells was significantly higher than in the control group. The CD94/NKG2A ligand, HLA-E, was detected at high levels in endometriotic tissue as messenger RNA transcript. Target cells bearing HLA-E were resistant to NK cell-mediated lysis in a CD94/NKG2A-dependent manner. CONCLUSION(S): Increased expression of CD94/NKG2A in peritoneal NK cells may mediate the resistance of endometriotic tissue to NK cell-mediated lysis, thus contributing to the progression of the disease. FAU - Galandrini, Ricciarda AU - Galandrini R AD - Department of Experimental Medicine, University "La Sapienza," Rome, Italy. ricciarda.galandrini@uniroma1.it FAU - Porpora, Maria Grazia AU - Porpora MG FAU - Stoppacciaro, Antonella AU - Stoppacciaro A FAU - Micucci, Federica AU - Micucci F FAU - Capuano, Cristina AU - Capuano C FAU - Tassi, Ilaria AU - Tassi I FAU - Di Felice, Alessia AU - Di Felice A FAU - Benedetti-Panici, Pierluigi AU - Benedetti-Panici P FAU - Santoni, Angela AU - Santoni A LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20070813 PL - United States TA - Fertil Steril JT - Fertility and sterility JID - 0372772 RN - 0 (HLA Antigens) RN - 0 (Histocompatibility Antigens Class I) RN - 0 (KLRC1 protein, human) RN - 0 (KLRC2 protein, human) RN - 0 (NK Cell Lectin-Like Receptor Subfamily C) RN - 0 (NK Cell Lectin-Like Receptor Subfamily D) RN - 0 (RNA, Messenger) RN - 0 (Receptors, Immunologic) RN - 0 (Receptors, Natural Killer Cell) SB - IM MH - Adult MH - Ascitic Fluid/*immunology/metabolism/pathology MH - Case-Control Studies MH - Disease Progression MH - Endometriosis/blood/*immunology/metabolism/pathology MH - Female MH - HLA Antigens/genetics/metabolism MH - Histocompatibility Antigens Class I/genetics/metabolism MH - Humans MH - Immune Tolerance/immunology MH - Immunity, Cellular/immunology MH - Killer Cells, Natural/metabolism/*pathology MH - Lymphocyte Count MH - Middle Aged MH - NK Cell Lectin-Like Receptor Subfamily C MH - NK Cell Lectin-Like Receptor Subfamily D/blood/*metabolism MH - RNA, Messenger/metabolism MH - Receptors, Immunologic/blood/*metabolism MH - Receptors, Natural Killer Cell MH - HLA-E Antigens EDAT- 2007/08/21 09:00 MHDA- 2008/07/17 09:00 CRDT- 2007/08/21 09:00 PHST- 2006/11/22 00:00 [received] PHST- 2007/05/04 00:00 [revised] PHST- 2007/05/04 00:00 [accepted] PHST- 2007/08/21 09:00 [pubmed] PHST- 2008/07/17 09:00 [medline] PHST- 2007/08/21 09:00 [entrez] AID - S0015-0282(07)01143-0 [pii] AID - 10.1016/j.fertnstert.2007.05.018 [doi] PST - ppublish SO - Fertil Steril. 2008 May;89(5 Suppl):1490-6. doi: 10.1016/j.fertnstert.2007.05.018. Epub 2007 Aug 13.